Viswa Colluru, Enveda Biosciences

A Re­cur­sion vet­er­an is map­ping plant life to chart a course to new ther­a­pies — and in­vestors like what they see

One of the ear­li­est em­ploy­ees at AI biotech Re­cur­sion Phar­ma­ceu­ti­cals is lead­ing a new com­pa­ny, and he’s just closed a hefty Se­ries A to get things mov­ing.

Enve­da Bio­sciences pulled in $51 mil­lion in the raise, the com­pa­ny an­nounced Tues­day morn­ing, with the goal of push­ing some of its pre­clin­i­cal pro­grams fur­ther along. Led by CEO Viswa Col­lu­ru, Enve­da aims to re­search how ma­chine learn­ing can uti­lize nat­ur­al bi­ol­o­gy to cre­ate new ther­a­pies for Wil­son’s Dis­ease, NASH and Parkin­son’s dis­ease, among oth­ers.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Life Sciences Senior Associate

General Catalyst

San Francisco, CA, USA